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The objective of microdosimetry was, and still is, to identify physical descriptions of the initial physical processes of ionising radi-
ation interacting with biological matter which correlate with observed radiobiological effects with a view to improve the under-
standing of radiobiological mechanisms and effects. The introduction of therapy with particles starting with fast neutrons
followed by negative pions, protons and light ions necessitated the application of biological weighting factors for absorbed dose
in order to account for differences of the relative biological effectiveness (RBE). Dedicated radiobiological experiments in
therapy beams with mammalian cells and with laboratory animals provided sets of RBE values which are used to evaluate empir-
ical ‘clinical RBE values’. The combination of such experiments with microdosimetric measurements in identical conditions
offered the possibility to establish semi-empirical relationships between microdosimetric parameters and results of RBE studies.
INTRODUCTION
Microdosimetry in its original meaning started more
than 50 y ago with the development and the use of
low-pressure, tissue-equivalent proportional counters
by H.H. Rossi (‘Rossi Counters’) (Figure 1)(1). The
European Commission made Microdosimetry a pri-
ority in its radiation protection research programme
of EURATOM and initiated in 1967 the series of the
by now 15 Microdosimetry Symposia.
Experimental microdosimetry with Rossi Counters
enables the measurement and quantification of the
energy imparted by single primary particles (‘single
events’) in microscopic volumes with dimensions
similar to that of biological entities such as cells or
cell nuclei. More precisely, the counters simulate bio-
logical matter of linear dimensions of the order of
micrometre by using tissue-equivalent material for the
counter walls and low-pressure tissue-equivalent
counting gas. The pulse-height distributions corres-
pond to energy deposition distributions in the simu-
lated microscopic volume. This technique provided a
new set of data that could be compared with data
obtained in LET computation developed at the same
period. More detailed information on the technique
and recent developments of it are given by L. Braby
(this Symposium).
APPLICATIONS OF MICRODOSIMETRY
The first microdosimetry symposium in 1967 focused
on work of Harald Rossi and his team(2, 3). The dis-
cussion of technical aspects of the then still new ex-
perimental microdosimetry took up a major part of
the Symposium, i.e. detector design, interpretation of
the results and general physical and dosimetric
aspects.
The Symposia also offered the possibility to
compare the different programmes of research in the
field of microdosimetry developed in the USA,
mainly in New York and in Europe and to stimulate
collaborations. The presentation and discussion of
conceptual and technical aspects of measurements
with low-pressure tissue-equivalent proportional coun-
ters continued to be a focus in subsequent Symposia
but increasingly the emphasis shifted towards the role
of microdosimetry in radiation biology and its applica-
tions in radiation protection and radiation therapy.
Alternative approaches to Rossi Counter microdosime-
try such as the variance method(4) and recombination
chamber dosimetry(5) were introduced, and computa-
tional methods such as track structure calculations
began to play an important role.
In 1983, the ICRU published a report on Micro-
dosimetry: Report 36(6). It includes the definition of
the microdosimetric quantities: the energy imparted
1, the lineal energy y and the specific energy z.
The ‘Rossi counter’ has been used for decades and
new techniques were investigated. Recent develop-
ments include Rossi type proportional counters with
simulated volumes smaller than 1 mm(7) and solid-
state microdosimeters based on silicon(8) and single-
crystal diamond detectors(9). The latter work was as
solid-state ionisation chambers. The prototypes range
from 300 nm to 5 mm in thickness of diamond (d ¼
3.52 g cm23). An overview on experimental microdo-
simetric techniques and their application can be
found in Braby (this Symposium).
Experimental microdosimetry confirmed that in
the irradiated material, the energy is deposited
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stochastically in small amounts (‘event sizes’) and
provided a method to quantify the energy deposition
distributions. Microdosimetric spectra, presented in
terms of lineal energy, y, reveal the large dynamic
range of energy depositions (Figures 2 and 3)(10, 11).
The spectra in Figure 2 have been measured for
photons (and electrons) at different energies. For ener-
gies of .1 MeV up to all energies used in therapy, the
microdosimetric spectra are similar to each other. No
relative biological effectiveness (RBE) difference could
thus be expected and actually no significant difference
has been observed. These radiation qualities can thus
be selected as a ‘robust’ reference for dosimetry, RBE
and clinical studies.
The distributions are normalised per logarithmic
interval and thus equal areas under the curve will con-
tribute equally to the specific energy. Lindborg(10),
cited in ICRU 36(6).
In contrast, significant differences in the microdosi-
metric spectra have been observed for X rays ,1
MeV (Figure 3).
These differences correlate with differences in RBE
observed in radiobiological experiments. In clinical
practice, an RBE of 1.15 (Ref. 60Co) was in the past
recommended for 200 kV (conventional) X rays in
therapy applications, but radiobiological data have
shown RBE values up to 2–3 at low doses for some
systems and endpoints(11, 12).
Figure 4 shows microdosimetric spectra for two
neutron beams, which were used in fast neutron
therapy, in comparison to a spectrum for 60Co. The
dynamic range of energy depositions is even larger
than for photons. A comprehensive study of corre-
lated microdosimetric measurements and radiobio-
logical experiments at European neutron therapy
facilities led to the derivation of an empirical bio-
logical weighting function r(y)(11, 13) (see Figure 5).
Although the derived weighting function repro-
duced the RBE values of the radiobiological experi-
ments with a good statistical significance(13), the
impact of this approach on clinical neutron therapy
was low largely due to the lack of clinically relevant
RBE values for different tissues.
Figure 1. Harald H. Rossi, Columbia University-New York,
the pioneer of microdosimetry(1).
Figure 2. Microdosimetric spectra for beams of photons and
electrons. Single-event specific-energy (z) distributions measured
in five different beams, at the maximum of the depth-dose
curves: (solid line) 60Co g rays. (dash dot line) 180 kV X rays
with HVL¼ 09 mm Cu. (plus symbol) 42 MV photons. (dot
line) 39 MeV electrons. (multiply symbol) 15 MeV electrons.
The distributions are normalized per logarithmic interval and
thus equal areas under the curves will contribute equally to the
specific energy. Lindborg (1976)(10), cited in ICRU 36 (1983)(6).
Figure 3. Microdosimetric spectra for monoenergetic X rays
for 1 mm simulated diameter. Photon energy in keV as
parameter, after Kliauga and Dvorak (1978), cited in ICRU
Report 36(6).
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MICRODOSIMETRY IN RADIOBIOLOGY
In the 15 Symposia on Microdosimetry, several bio-
logical models and their potential implications in ra-
diation protection and therapy were presented and
discussed based or derived from microdosimetry and
results obtained in radiation physics research.
The ‘Theory of dual radiation action’ by Kellerer
and Rossi(14, 15), which is based on microdosimetric
data and concepts, was discussed intensively in several
symposia in the 1970s. The theory, initially developed
for radiation protection purposes, was extended to
several types of applications, in particular, radiation
therapy.
Today, the use of the linear-quadratic model in ra-
diation therapy is reasonably well validated and influ-
ences all radiation therapy techniques. It is used to
evaluate the effect of several factors on the clinical




Microdosimetric measurements and data were used in
the context of therapy with high-energy photons and
electrons(10), with fast neutrons(11, 13, 16) and with
negative pions(17). Using this experience, microdosi-
metry is now also applied in particle therapy.
QUANTITIES, DEFINITIONS AND UNITS
Absorbed dose is the fundamental quantity in radi-
ation therapy. When reporting radiation therapy proce-
dures, it should always be reported together with the
complete description of the irradiation conditions. The
clinical effects depend, however, on radiation quality
and several other factors including fractionation,
overall treatment time, tumour type and location(18).
In order to account for all factors, ICRU has pre-
sented a clinically more relevant quantity: the equi-ef-
fective dose(19). It is defined as the absorbed dose that,
when delivered under different technical and irradi-
ation conditions, produces the same probability of a
specific endpoint as under the reference conditions.
The equi-effective dose is the product of the absorbed
dose and a weighting factor which takes into account
all factors listed above that can influence the biologic-
al/clinical effects. These factors have to be combined
and are not independent from each other. At present,
accounting for radiation quality is still using micro-
dosimetric data but empirical information. The equi-




The main argument in favour of proton therapy is an
improved physical selectivity (Bragg peak and finite
range) compared with photon beams. No significant
radiobiological benefit has to be expected compared
with the modern photon techniques.
Radiobiological data show an increase of RBE
ranging from 0 to 20 % relative to 60Co. This is in agree-
ment with the microdosimetric data(13, 20) (Figure 5).
The ICRU recommends a generic RBE of 1.1 for clin-
ical applications(21). Although this recommendation
Figure 5. Microdosimetric spectra in a 90 MeV modulated-
energy proton beam. Measurements are performed in the
initial plateau, at the proximal, middle and distal positions
in the Spread-Out Bragg Peak (SOBP) (as indicated on the
top of the figure). The shift of the spectra towards higher y
values with an increasing depth which correlates with the 10
% higher value of the proton RBE compared with the 60Co.
Figure 4. Comparison of the microdosimetric spectra y d(y)
vs. y obtained for 60Co g rays, d(14) þ Be neutrons and
p(65) þ Be neutrons, i.e. the lowest and highest neutron
energies applied for therapy(11, 13).
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seems justified, recent data have shown a further RBE
increase between the middle and the end of the
Spread-Out Bragg Peak (SOBP). Its clinical signifi-
cance is still a matter of debate. An example for intes-
tinal crypt cells is shown in Figure 6(22). Accurate
animal data and beam positioning allow one to irradi-
ate part of the intestine at different depths of the
SOBP.
The biological weighting function r(y) (right ordin-
ate) was obtained for intestinal crypt cells. The in-
crease of the r(y) function .10 keV mm– 1 is related
to the RBE increase at the distal SOBP region(13, 20).
MICRODOSIMETRTY IN CARBON-ION
THERAPY
Like proton beams, carbon-ion beams have a high
physical selectivity. In addition, from a radiobiologic-
al point of view, because they are high-LET radiation,
the clinical results are less dependent on dose per frac-
tion and relatively more effective for late than early
effects(18). They have LET and microdosimetric y
spectra similar to fast neutrons as used in therapy
(Figure 4). A clinical benefit could thus be expected
for some tumour types (e.g. salivary gland and pros-
tate tumours, slowly growing sarcomas)(23 – 25).
Evaluation and selection of RBE values and equi-
effective dose for prescribing, planning and reporting
carbon-ion therapy is a complex issue. Two different
irradiation techniques are used today: at NIRS in
Japan, where passive scattering was used initially and
in Darmstadt-Heidelberg, Germany, where a scan-
ning-beam technique is used.
At NIRS, a ‘clinical RBE’ of 3 is assumed for carbon
ions at a point located 2/3 of the depth of the SOBP,
where the local lineal energy y is 80 keV mm21
(Figure 7)(26). This RBE value of 3 was, in the past, the
‘clinical RBE’ adopted for fast neutron therapy in the
NIRS experience. The microdosimetric spectra for fast
neutron beams are wide but an average value of 80
keV mm21 could be derived (Figure 4)(18). The physical,
Figure 6. Dose–effect relationships for crypt regeneration in mice after irradiation at different depths in the iThemba 200
MeV clinical proton beam. (a) SOBP ¼ 7 cm. The open and closed circles correspond to irradiations in the middle and end
of the SOBP, respectively. Parallel exponential regression curves are fitted by the weighted least squares method (95 %
confidence intervals). (b) SOBP ¼ 3 cm. The same presentation. The triangles correspond to irradiations halfway between
the middle and end of the SOBP(22).
Figure 7. Microdosimetric spectra of lineal energy, y d(y),
measured for 60Co and a 290 MeV u21 carbon-ion beam
(SOBP ¼ 60 mm) at four typical depths: 28 mm (entrance),
86 mm proximal SOBP, 136 mm (rear SOBP) and 161 mm
(fragmentation tail)(26).
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radiobiological and clinical depth–dose curves are com-
pared in Figure 8(27).
In Darmstadt-Heidelberg, where a scanning-beam
technique is used, the equi-effective dose is computed
point-by-point (voxel) in the target volume based on
local LET, absorbed dose, dose per fraction and
selected biological endpoint. For current treatment
planning, the LEM model is used(28, 29).
CONCLUSION
The development of microdosimetry by Harald Rossi,
in the 1960s, has contributed to the authors under-
standing of the biological effects of ionising radia-
tions and influenced teaching programmes.
Absorbed dose is the fundamental quantity in radi-
ation therapy and must always be reported. However,
clinical effects depend also on other factors including
radiation quality. In order to provide a pragmatic, em-
pirical method for clinical practice, ICRU is propos-
ing a quantity, the equi-effective dose.
When comparing different therapy beams, report-
ing clinical RBE values imply that the absorbed doses
are accurately known and that the dose distributions
in the target volume are comparable. This has been
achieved only for selected radiobiological systems and
techniques: few experimental protocols for this
purpose have been published to date (cells in vitro, in-
testinal crypt cells in vivo). In existing clinical situa-
tions, the dose distributions are often not comparable
(e.g. carbon-ion beams compared with photon irra-
diations), it is difficult to meet the required criteria.
Specification of radiation quality is of particular
importance for therapy with particles, fast neutrons
and ions. In spite of many years of research, microdo-
simetry has not yet provided a generally applicable
method for accounting of radiation quality in particle
therapy.
Earlier attempts to establish a microdosimetry-
based method to account for radiation quality for fast
neutron therapy were promising(13). However, due to
the paucity of clinically relevant radiobiological data
and with the decline of the number of active neutron
therapy facilities also the interest in using microdosi-
metric approaches to deriving clinical RBE declined.
However, renewed interest in using microdosimetry
for radiation quality quantification has developed for
therapy with C-ions(26, 30), where the clinical RBE
varies significantly within and outside the treatment
volume.
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